Ischemic stroke after COVID-19 bivalent vaccine administration in patients aged 65 years and older: analysis of nation-wide patient electronic health records in the United States

1. Introduction

On January 13, 2023, the Centers for Disease Control and Prevention (CDC) announced that its Vaccine Safety Datalink met the threshold to investigate the risk of ischemic stroke (IS) within three weeks of administration of the Pfizer/BioNTech novel coronavirus disease-2019 (COVID-19) bivalent vaccine (Pfizer bivalent booster)¹. No such concern was raised in the CDC’s statement for the Moderna COVID-19 bivalent vaccine (Moderna bivalent booster). The earlier monovalent Moderna and Pfizer vaccines display no increased risk for IS in the general American population²; however, COVID-19 infection itself appears to be a risk factor for IS in patients ages 65 years and over³. This CDC announcement was therefore unanticipated, since then both the Food and Drug Administration and European Medicines Agency have reported no increased IS risk for the Pfizer bivalent vaccine in their respective databases^4,5. In response to the inconsistent findings among these major regulatory bodies and the wide use of COVID-19 bivalent vaccines in older adults, we set out to gauge the hazard of IS in patients ages 65 years and over administered the Pfizer bivalent booster in a nationwide, frequently updated platform of electronic health record (EHR) data on over 90 million unique patients in the United States.

2. Methods

3. Results

The study population of patients who were age 65 years or over at the time of booster administration on or before November 25, 2022 included 43,216 who received the Pfizer bivalent booster, 4,267 who received the Moderna bivalent booster, and 100,583 who received a Pfizer or Moderna monovalent booster. The characteristics of the Pfizer bivalent and Moderna bivalent cohorts before and after propensity-score matching are shown in Table 1. After matching, the Pfizer bivalent cohort was comprised of 4,267 patients, with an average age of 73.7 years (44.43% male, 76.59% white) (Table 1). The Moderna bivalent cohort was comprised of 4,267 patients, with an average age of 74.0 years (44.08% male, 77.39% white) (Table 1). Details on propensity-score matching between the Pfizer bivalent and monovalent cohorts are available in eTable 2 (eMethod).

Within the Pfizer bivalent cohort of 43,216 patients, there is no increase in IS encounters within the 1-21 days after versus before booster administration (127 versus 141 IS encounters, P = 0.43). However, there are fewer IS encounters in the 22-42 days after versus before booster administration (109 vs 189 IS encounters, P <0.001).

There was no significant difference in the hazard of IS encounters between the Pfizer bivalent and Moderna bivalent cohorts at 1-21- or 22-42-days post-administration: HR = 0.59 (0.31, 1.11), 0.73 (0.33, 1.60), respectively (Figure 1). Compared to the monovalent cohort, there is reduced hazard of IS encounters in the Pfizer bivalent cohort at both timepoints: HR = 0.24 (0.19, 0.29), 0.25 (0.20, 0.31), respectively (Figure 1). There was also reduced hazard of first-time IS encounters in the Pfizer bivalent cohort compared to the monovalent cohort at both time points, but this was only significant at 22-42 days post-administration: HR = 0.63 (0.35, 1.15), 0.32 (0.17, 0.60), respectively (Figure 1).

• Download figure
• Open in new tab

Figure 1:

Hazard ratio for ischemic stroke between propensity-score matched cohorts 1-21 and 22-42 days after administration of Pfizer bivalent, Moderna bivalent, or Pfizer/Moderna monovalent COVID-19 vaccine.

4. Discussion

The hazard for IS encounters did not differ significantly between the matched Pfizer and Moderna bivalent cohorts at both 1-21 and 22-42 days after booster administration. We also observed a reduced hazard of IS encounters in the Pfizer bivalent versus monovalent cohort, perhaps due to bivalent boosters providing stronger protection against severe COVID-19 infection and hospitalization than monovalent vaccines^11,12. Limitations of this study include the use of the TriNetX platform, which is not a random sampling of the entire United States population over the age of 65 years; therefore, the generalizability of the results is unclear. While the Pfizer and Moderna bivalent vaccines were approved in August 2022, their monovalent counterparts were approved earlier. Therefore, although patients in the Pfizer bivalent cohort and monovalent cohort were followed for the same length of time, the circulating SARS-Cov-2 virus variants that patients in these two cohorts encountered could be different. Nevertheless, our analysis provides no evidence that American patients ages 65 and over have an increased hazard of IS after Pfizer bivalent booster administration; patients and healthcare providers should not be dissuaded from receiving or administering this booster vaccine.

Contributors

RX conceived of, designed, and supervised the study and contributed to manuscript preparation. MPG designed and conducted the study and drafted the manuscript. PBD critically contributed to study design, result interpretation, and manuscript preparation. DCK provided access to the TriNetX platform and critically reviewed. All authors approved the final manuscript. We confirm the originality of content. MPG had full access to all the analysis in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Declaration of interests

MPG, PBD, DCK, RX have no financial interests to disclose.

Role of Funder/Sponsor Statement

The funders have no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentation

No